从多囊卵巢综合征到多内分泌代谢性卵巢综合征:妇产科医生须知
多囊卵巢综合征经国际共识更名为多内分泌代谢性卵巢综合征,新名称纠正了卵巢形态的误称并强调终身内分泌代谢属性。该病影响约10%至13%育龄女性,与不良妊娠结局及远期心血管代谢风险相关,但常被漏诊且未纳入产科风险预警。诊断标准不变,改变的是临床框架。
要点
- 新名称强调该病为终身内分泌代谢性疾病,而非单纯卵巢囊肿或生育问题。
- 妊娠期与流产、妊娠期糖尿病、高血压疾病、早产等多种不良结局相关。
- 诊断标准不变:排卵障碍、高雄激素、AMH或超声多囊三项中满足两项。
核心结论
- 多囊卵巢综合征已更名为多内分泌代谢性卵巢综合征,临床框架应从卵巢局部转向终身内分泌代谢管理。
研究设计与样本
- 本文为特别报告,基于国际多步骤共识过程(获56个专业和患者组织支持)讨论更名理由并综述相关证据。
主要发现
- 多内分泌代谢性卵巢综合征影响约10%至13%育龄女性,与胰岛素抵抗、高雄激素、排卵功能障碍、心理疾病及终身心血管代谢风险相关。
- 妊娠期与流产、妊娠期糖尿病、妊娠期高血压疾病、剖宫产、早产、胎儿生长受限、低出生体重及小于胎龄儿风险升高相关,许多关联在调整年龄和体重指数后仍持续。
- 该病未在首次产科就诊时常规作为产科风险修饰因素记录,也未一致嵌入产前决策支持路径。
- 患者心理、代谢及长期心血管代谢风险的筛查和咨询不一致。
关键数值与推荐
- 诊断标准不变:成人满足以下三项中两项:月经不规律和排卵功能障碍、临床或生化高雄激素、抗苗勒管激素水平升高或卵巢超声显示多个卵泡。
临床怎么用
- 妇产科医生应在首次产科就诊时识别多内分泌代谢性卵巢综合征并纳入风险预警。
- 应加强心理、代谢及长期心血管代谢风险的筛查与咨询,并协调从青春期至绝经后的全程管理。
局限性
- 本文为特别报告,非系统综述或原始研究,未提供新的原始数据或定量合并分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Polycystic ovary syndrome has been renamed polyendocrine metabolic ovarian syndrome following a multistep international consensus process endorsed by 56 professional and patient organizations. The new name corrects a longstanding misnomer. The characteristic ovarian morphology reflects numerous arrested antral follicles, not pathologic cysts, and the legacy term has reinforced an overly ovarian and fertility-centered view of a lifelong endocrine-metabolic condition. For obstetrician-gynecologists, this reframing has immediate clinical relevance. Polyendocrine metabolic ovarian syndrome affects approximately 10% to 13% of reproductive-age women, yet it remains underdiagnosed and inconsistently documented in routine care. It is associated with insulin resistance, hyperandrogenism, ovulatory dysfunction, psychological morbidity, and cardiometabolic risk across the life course. During pregnancy, polyendocrine metabolic ovarian syndrome is linked to higher risks of miscarriage, gestational diabetes, hypertensive disorders of pregnancy, cesarean delivery, preterm birth, fetal growth restriction, low birthweight, and small-for-gestational-age infants, with many associations persisting after adjustment for age and body mass index. Despite this evidence, polyendocrine metabolic ovarian syndrome is not routinely captured as an obstetric risk modifier at the first obstetric visit, nor is it consistently embedded in antenatal decision-support pathways. Patients also remain inconsistently screened and counseled for psychological, metabolic, and long-term cardiometabolic risks. This Special Report discusses the rationale for the polycystic ovary syndrome-to-polyendocrine metabolic ovarian syndrome rename, reviews evidence linking polyendocrine metabolic ovarian syndrome with adverse pregnancy and offspring outcomes and outlines practical implications for obstetric and gynecologic care. Diagnostic criteria remain unchanged; namely, 2 of the following 3: irregular menstrual cycles and ovulatory dysfunction, clinical or biochemical hyperandrogenism, and elevated anti-Müllerian hormone levels or multiple follicles on ovarian ultrasound in adults. What changes is the clinical frame. Obstetrician-gynecologists are uniquely positioned to improve earlier diagnosis, risk recognition, counseling, and coordinated care from adolescence through menopause and beyond.
引用
- Bahri-Khomami M, Hoeger KM, Huddleston H, et al. From polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome: what obstetricians and gynecologists need to know. Am J Obstet Gynecol. 2026. PMID: 42665241. doi:10.1016/j.ajog.2026.08.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。